Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
Exousia Pro (OTCPINK:MAJI) has announced plans for an IRB study to evaluate their innovative CBD-loaded exosome technology for edibles. The study will compare their proprietary exosome-based CBD gummies against standard formulations, focusing on bioavailability and plasma levels.
The company's technology utilizes exosomes as protective nano-carriers that shield CBD from digestive degradation, potentially solving a major challenge in the edibles market. The comparative trial is scheduled for Q4 2025, with participants testing both formulations through a series of blood draws to measure effectiveness.
President Matt Dwyer highlighted this as a significant opportunity, noting strong initial interest from potential partners in the US and Europe. The study aims to validate their technology's superiority and establish licensing opportunities in the cannabinoid and nutraceutical industries.
Exousia Pro (OTCPINK:MAJI) ha annunciato piani per uno studio IRB per valutare la loro innovativa tecnologia di esosome caricate con CBD destinata agli alimenti. Lo studio metterà a confronto i loro gummy CBD basati su esosome proprietari con formulazioni standard, concentrandosi sulla biodisponibilità e sui livelli nel plasma.
La tecnologia dell'azienda utilizza gli esosomi come nano-carrier protettivi che salvaguardano il CBD dalla degradazione digestiva, potenzialmente risolvendo una delle principali sfide nel mercato degli edibili. Il trial comparativo è previsto per Q4 2025, con i partecipanti che testeranno entrambe le formulazioni tramite una serie di prelievi di sangue per misurarne l'efficacia.
Il presidente Matt Dwyer ha sottolineato questa come una significativa opportunità, rilevando un forte interesse iniziale da parte di potenziali partner negli Stati Uniti e in Europa. Lo studio mira a validare la superiorità della loro tecnologia e a avviare opportunità di licensing nei settori cannabinoidi e nutraceutici.
Exousia Pro (OTCPINK:MAJI) ha anunciado planes para un estudio IRB que evaluará su innovadora tecnología de exosomas cargados de CBD para productos comestibles. El estudio comparará sus gominolas de CBD basadas en exosomas propietarias con formulaciones estándar, enfocándose en la biodisponibilidad y los niveles en plasma.
La tecnología de la empresa utiliza exosomas como nanoportadores protectores que protegen el CBD de la degradación digestiva, potencialmente solucionando uno de los grandes retos del mercado de comestibles. El ensayo comparativo está programado para Q4 2025, con participantes probando ambas formulaciones a través de una serie de extracciones de sangre para medir la efectividad.
El presidente Matt Dwyer destacó esto como una oportunidad significativa, señalando un fuerte interés inicial de posibles socios en EE. UU. y Europa. El estudio busca validar la superioridad de su tecnología y establecer oportunidades de licenciamiento en las industrias de cannabinoides y nutracéuticos.
Exousia Pro (OTCPINK:MAJI)가 식용으로 사용될 CBD 로딩 엑소좀 기술을 평가하기 위한 IRB 연구 계획을 발표했습니다. 이 연구는 독점 엑소좀 기반 CBD 구미를 표준 제형과 비교하고 생체이용률과 혈장 수치를 중심으로 평가합니다.
회사는 엑소좀을 보호 나노 운반체로 활용하여 CBD를 소화 효소로부터 보호하고, 식용 시장의 주요 도전과제를 해결할 수 있는 가능성을 보여줍니다. 비교 임상은 2025년 4분기에 예정되어 있으며 참여자들이 혈액 채취를 통해 두 제형의 효과를 측정합니다.
매트 듀이어 사장은 이를 중요한 기회로 보며 미국과 유럽의 잠재적 파트너로부터 강한 초기 관심을 언급했습니다. 이 연구는 그들의 기술 우수성을 검증하고 칸나비노이드 및 영양보조제 산업에서 라이선스 기회를 확립하는 것을 목표로 합니다.
Exousia Pro (OTCPINK:MAJI) a annoncé des plans pour une étude IRB afin d’évaluer leur technologie innovante d’exosomes chargés en CBD pour les comestibles. L’étude comparera leurs gommes CBD basées sur des exosomes propriétaires à des formulations standard, en se concentrant sur la biodisponibilité et les niveaux plasmatiques.
La technologie de l’entreprise utilise des exosomes comme nanoconteneurs protecteurs qui protègent le CBD de la dégradation digestive, potentiellement résolvant l’un des grands défis du marché des produits comestibles. L’essai comparatif est prévu pour Q4 2025, avec des participants testant les deux formulations au cours d’une série de prises de sang pour mesurer l’efficacité.
Le président Matt Dwyer a souligné que c’était une opportunité significative, notant un fort intérêt initial de partenaires potentiels aux États-Unis et en Europe. L’étude vise à valider la supériorité de leur technologie et à établir des opportunités de licensing dans les secteurs cannabinoïdes et nutraceutiques.
Exousia Pro (OTCPINK:MAJI) hat Pläne für eine IRB-Studie angekündigt, um ihre innovative CBD-beladene Exosom-Technologie für Lebensmittel zu bewerten. Die Studie wird ihre proprietären Exosom- basierten CBD-Gummis mit Standardformulierungen vergleichen und dabei Bioverfügbarkeit und Plasmaspiegel in den Fokus stellen.
Die Technologie des Unternehmens nutzt Exosomen als schützende Nano-Träger, die CBD vor der Verdauungsdegradation schützen und damit möglicherweise eine der größten Herausforderungen im Bereich der essbaren Produkte lösen. Der Vergleichsversuch ist für Q4 2025 vorgesehen, wobei die Teilnehmer beide Formulierungen durch eine Reihe von Blutabnahmen auf Wirksamkeit testen.
Präsident Matt Dwyer hob dies als signifikante Chance hervor und vermerkte starkes initiales Interesse potenzieller Partner in den USA und Europa. Ziel der Studie ist es, die Überlegenheit ihrer Technologie zu validieren und Lizenzmöglichkeiten in den Cannabinoid- und Nutraceutical-Branchen zu schaffen.
Exousia Pro (OTCPINK:MAJI) أعلنت عن خطط لدراسة IRB لتقييم تقنية الإكسوسومات المحملة بـ CBD المبتكرة للاستخدامات الغذائية. ستقارن الدراسة حلوى CBD المعتمدة على الإكسوسومات المملوكة للشركة بالتركيبات القياسية، مع التركيز على التوافر الحيوي ومستويات البلازما.
تستخدم تقنية الشركة الإكسوسومات كمحمّلات نانوية واقية تحمي CBD من التحلل الهضمي، ما قد يحل إحدى التحديات الرئيسية في سوق المنتجات القابلة للأكل. من المقرر إجراء التجربة المقارنة في الربع الرابع من 2025، حيث يختبر المشاركون كلا التكوينين من خلال سلسلة من سحب الدم لقياس الفعالية.
أشار الرئيس مارت ديوير إلى أنها فرصة كبيرة، مع ملاحظة اهتماماً أولياً قوياً من شركاء محتملين في الولايات المتحدة وأوروبا. تهدف الدراسة إلى التحقق من تفوق تقنيتهم وفتح فرص ترخيص في صناعات القنب والمكملات الغذائية.
Exousia Pro (OTCPINK:MAJI) 已宣布计划进行 IRB 研究，以评估其用于食品的创新CBD负载的外泌体技术。该研究将比较其专有的基于外泌体的CBD软糖与现有常规配方，重点关注生物利用度和血浆水平。
该公司技术利用外泌体作为保护性纳米载体，能保护CBD免受消化降解，可能解决膳食市场的一大挑战。比较性试验计划在2025年第四季度进行，参与者将通过一系列血液抽取来测量效果。
总裁Matt Dwyer强调这是一个重大机会，指出美国和欧洲潜在合作伙伴的初步强烈兴趣。该研究旨在验证其技术的优越性，并在大麻素和营养保健品行业建立许可机会。
- None.
- Study results not yet available or guaranteed
- Currently in clinical-stage with no commercialized products
- Timeline dependent on successful Q4 2025 study completion
ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan to conduct an Institutional Review Board (IRB) study that could fundamentally transform the cannabinoid edible and nutraceutical markets.
The study is designed to demonstrate the dramatically enhanced efficacy of CBD-loaded exosomes in oral delivery. This research is predicated on the known ability of our proprietary exosomes to survive the digestive tract and deliver their payload directly to the small intestine.
The Study and Its Disruptive Potential
Current CBD and THC edibles often suffer from significant loss of effectiveness due to degradation within the digestive system. Exousia Pro's technology is engineered to solve this challenge.
The Exosome Advantage: Our exosomes act as natural, protective nano-carriers, shielding the CBD from the harsh environment of the stomach and ensuring a full payload is delivered for absorption.
Study Design: The IRB study will be a comparative trial involving two different CBD gummies: one utilizing Exousia Pro's CBD-loaded exosomes and one utilizing a standard formulation. Participants will ingest each formulation on separate days, followed by multiple blood draws to precisely measure and compare CBD bioavailability and plasma levels.
Expected Outcome: The company expects the study to conclusively demonstrate that our exosome-loaded formulation delivers a significantly higher and more efficient payload, thereby maximizing the therapeutic effects for the consumer.
We anticipate that the study will be conducted within the fourth quarter.
"This is a low-hanging fruit opportunity for Exousia Pro that can create an immediate and substantial impact on the company," stated Matt Dwyer, President of Exousia Pro, Inc. "The multi-billion-dollar edible market is ripe for disruption. Our technology offers a superior delivery mechanism that dramatically enhances the existing products on the shelf. This study is the critical step to proving the science and unlocking a massive commercial opportunity. Initial inquiries with potential partners in both the United States and Europe have yielded highly positive feedback, affirming the global commercial interest in this revolutionary delivery system."
The results of this study are expected to open immediate pathways for licensing and partnership opportunities across the entire cannabinoid and nutraceutical industries, establishing a new gold standard for edible product efficacy.
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Exousia Pro, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the purpose of Exousia Pro's (MAJI) new CBD exosome study?
When will Exousia Pro (MAJI) conduct its CBD exosome study?
How does Exousia Pro's CBD exosome technology work?
What market opportunity is Exousia Pro (MAJI) targeting with its CBD exosome technology?
How will Exousia Pro's CBD exosome study be conducted?
